A Phase II Study of CyBorD Plus Daratumumab for Patients with MGRS

The purpose of this study is to find out whether a combination of drugs is a safe treatment for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. The combination of drugs in this study is cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC. In addition, we will find out whether the study drug combination is an effective treatment for these conditions.